Concordance of DNA methylation pattern in plasma and tumor DNA of Egyptian hepatocellular carcinoma patients

Priyanka Iyer, Abdel Rahman Zekri, Chu Wei Hung, Emily Schiefelbein, Kadry Ismail, Ahmed Hablas, Ibrahim A. Seifeldin, Amr S Soliman

Research output: Contribution to journalArticle

53 Citations (Scopus)

Abstract

Hepatocellular carcinoma (HCC) is the fifth most common cancer and the fourth leading cause of cancer mortality globally. HCC incidence has doubled in Egypt in the past 10 years, which could be attributed to the high prevalence of hepatitis C virus (HCV) and hepatitis B virus (HBV), although HBV rates have declined after the introduction of the vaccine in 1992. Aberrant DNA methylation may play an important role in hepatocarcinogenesis. Liver biopsy is the current gold standard for methylation studies; however, imaging techniques often suffice for diagnosis making tissue samples increasingly scarce. The efficacy of conducting DNA methylation studies in molecular epidemiology using plasma DNA is still unclear. We compared tumor methylation profile for the tumor suppressor genes APC, FHIT, p15, p16, and E-cadherin in tumor tissues and plasma to test the concordance between the two types of specimen from the same HCC patients. Twenty-eight HCC patients with matching tissue and plasma DNA were recruited from a case-control study in Gharbiah, Egypt. Concordance between the tissue and plasma was statistically significant in all five genes as follows: APC (23/28, 82.1%, p=0.001), FHIT (24/28, 85.7%, p=.0001), p15 (25/28, 89.2%, p=0.045), p16 (19/28, 67.9%, p=0.037), and E-cadherin (22/28, 78.5%, p=0.0008). The average specificity was 90%, 86%, 96%, 86%, and 100%, respectively. There was no significant association between methylation and hepatitis viral infection for any of the genes tested in this study. Plasma DNA can be reliable for testing methylation profile in liver cancer patients in this population. Future studies on a larger sample size should investigate methylation profile in populations with higher rates of HBV, HCV, and other risk factors.

Original languageEnglish (US)
Pages (from-to)107-111
Number of pages5
JournalExperimental and Molecular Pathology
Volume88
Issue number1
DOIs
StatePublished - Feb 1 2010

Fingerprint

Methylation
DNA Methylation
Viruses
Tumors
Hepatocellular Carcinoma
Plasmas
Hepatitis B virus
DNA
Tissue
Genes
Egypt
Cadherins
Neoplasms
Hepacivirus
Liver
Molecular Epidemiology
Biopsy
Virus Diseases
Liver Neoplasms
Tumor Suppressor Genes

Keywords

  • Egypt
  • HCC
  • Liver
  • Meththylation
  • Plasma
  • Tumor tissue

ASJC Scopus subject areas

  • Pathology and Forensic Medicine
  • Molecular Biology
  • Clinical Biochemistry

Cite this

Iyer, P., Zekri, A. R., Hung, C. W., Schiefelbein, E., Ismail, K., Hablas, A., ... Soliman, A. S. (2010). Concordance of DNA methylation pattern in plasma and tumor DNA of Egyptian hepatocellular carcinoma patients. Experimental and Molecular Pathology, 88(1), 107-111. https://doi.org/10.1016/j.yexmp.2009.09.012

Concordance of DNA methylation pattern in plasma and tumor DNA of Egyptian hepatocellular carcinoma patients. / Iyer, Priyanka; Zekri, Abdel Rahman; Hung, Chu Wei; Schiefelbein, Emily; Ismail, Kadry; Hablas, Ahmed; Seifeldin, Ibrahim A.; Soliman, Amr S.

In: Experimental and Molecular Pathology, Vol. 88, No. 1, 01.02.2010, p. 107-111.

Research output: Contribution to journalArticle

Iyer, P, Zekri, AR, Hung, CW, Schiefelbein, E, Ismail, K, Hablas, A, Seifeldin, IA & Soliman, AS 2010, 'Concordance of DNA methylation pattern in plasma and tumor DNA of Egyptian hepatocellular carcinoma patients', Experimental and Molecular Pathology, vol. 88, no. 1, pp. 107-111. https://doi.org/10.1016/j.yexmp.2009.09.012
Iyer, Priyanka ; Zekri, Abdel Rahman ; Hung, Chu Wei ; Schiefelbein, Emily ; Ismail, Kadry ; Hablas, Ahmed ; Seifeldin, Ibrahim A. ; Soliman, Amr S. / Concordance of DNA methylation pattern in plasma and tumor DNA of Egyptian hepatocellular carcinoma patients. In: Experimental and Molecular Pathology. 2010 ; Vol. 88, No. 1. pp. 107-111.
@article{9b5e0d3c498743eeaefa17c73ea3c124,
title = "Concordance of DNA methylation pattern in plasma and tumor DNA of Egyptian hepatocellular carcinoma patients",
abstract = "Hepatocellular carcinoma (HCC) is the fifth most common cancer and the fourth leading cause of cancer mortality globally. HCC incidence has doubled in Egypt in the past 10 years, which could be attributed to the high prevalence of hepatitis C virus (HCV) and hepatitis B virus (HBV), although HBV rates have declined after the introduction of the vaccine in 1992. Aberrant DNA methylation may play an important role in hepatocarcinogenesis. Liver biopsy is the current gold standard for methylation studies; however, imaging techniques often suffice for diagnosis making tissue samples increasingly scarce. The efficacy of conducting DNA methylation studies in molecular epidemiology using plasma DNA is still unclear. We compared tumor methylation profile for the tumor suppressor genes APC, FHIT, p15, p16, and E-cadherin in tumor tissues and plasma to test the concordance between the two types of specimen from the same HCC patients. Twenty-eight HCC patients with matching tissue and plasma DNA were recruited from a case-control study in Gharbiah, Egypt. Concordance between the tissue and plasma was statistically significant in all five genes as follows: APC (23/28, 82.1{\%}, p=0.001), FHIT (24/28, 85.7{\%}, p=.0001), p15 (25/28, 89.2{\%}, p=0.045), p16 (19/28, 67.9{\%}, p=0.037), and E-cadherin (22/28, 78.5{\%}, p=0.0008). The average specificity was 90{\%}, 86{\%}, 96{\%}, 86{\%}, and 100{\%}, respectively. There was no significant association between methylation and hepatitis viral infection for any of the genes tested in this study. Plasma DNA can be reliable for testing methylation profile in liver cancer patients in this population. Future studies on a larger sample size should investigate methylation profile in populations with higher rates of HBV, HCV, and other risk factors.",
keywords = "Egypt, HCC, Liver, Meththylation, Plasma, Tumor tissue",
author = "Priyanka Iyer and Zekri, {Abdel Rahman} and Hung, {Chu Wei} and Emily Schiefelbein and Kadry Ismail and Ahmed Hablas and Seifeldin, {Ibrahim A.} and Soliman, {Amr S}",
year = "2010",
month = "2",
day = "1",
doi = "10.1016/j.yexmp.2009.09.012",
language = "English (US)",
volume = "88",
pages = "107--111",
journal = "Experimental and Molecular Pathology",
issn = "0014-4800",
publisher = "Academic Press Inc.",
number = "1",

}

TY - JOUR

T1 - Concordance of DNA methylation pattern in plasma and tumor DNA of Egyptian hepatocellular carcinoma patients

AU - Iyer, Priyanka

AU - Zekri, Abdel Rahman

AU - Hung, Chu Wei

AU - Schiefelbein, Emily

AU - Ismail, Kadry

AU - Hablas, Ahmed

AU - Seifeldin, Ibrahim A.

AU - Soliman, Amr S

PY - 2010/2/1

Y1 - 2010/2/1

N2 - Hepatocellular carcinoma (HCC) is the fifth most common cancer and the fourth leading cause of cancer mortality globally. HCC incidence has doubled in Egypt in the past 10 years, which could be attributed to the high prevalence of hepatitis C virus (HCV) and hepatitis B virus (HBV), although HBV rates have declined after the introduction of the vaccine in 1992. Aberrant DNA methylation may play an important role in hepatocarcinogenesis. Liver biopsy is the current gold standard for methylation studies; however, imaging techniques often suffice for diagnosis making tissue samples increasingly scarce. The efficacy of conducting DNA methylation studies in molecular epidemiology using plasma DNA is still unclear. We compared tumor methylation profile for the tumor suppressor genes APC, FHIT, p15, p16, and E-cadherin in tumor tissues and plasma to test the concordance between the two types of specimen from the same HCC patients. Twenty-eight HCC patients with matching tissue and plasma DNA were recruited from a case-control study in Gharbiah, Egypt. Concordance between the tissue and plasma was statistically significant in all five genes as follows: APC (23/28, 82.1%, p=0.001), FHIT (24/28, 85.7%, p=.0001), p15 (25/28, 89.2%, p=0.045), p16 (19/28, 67.9%, p=0.037), and E-cadherin (22/28, 78.5%, p=0.0008). The average specificity was 90%, 86%, 96%, 86%, and 100%, respectively. There was no significant association between methylation and hepatitis viral infection for any of the genes tested in this study. Plasma DNA can be reliable for testing methylation profile in liver cancer patients in this population. Future studies on a larger sample size should investigate methylation profile in populations with higher rates of HBV, HCV, and other risk factors.

AB - Hepatocellular carcinoma (HCC) is the fifth most common cancer and the fourth leading cause of cancer mortality globally. HCC incidence has doubled in Egypt in the past 10 years, which could be attributed to the high prevalence of hepatitis C virus (HCV) and hepatitis B virus (HBV), although HBV rates have declined after the introduction of the vaccine in 1992. Aberrant DNA methylation may play an important role in hepatocarcinogenesis. Liver biopsy is the current gold standard for methylation studies; however, imaging techniques often suffice for diagnosis making tissue samples increasingly scarce. The efficacy of conducting DNA methylation studies in molecular epidemiology using plasma DNA is still unclear. We compared tumor methylation profile for the tumor suppressor genes APC, FHIT, p15, p16, and E-cadherin in tumor tissues and plasma to test the concordance between the two types of specimen from the same HCC patients. Twenty-eight HCC patients with matching tissue and plasma DNA were recruited from a case-control study in Gharbiah, Egypt. Concordance between the tissue and plasma was statistically significant in all five genes as follows: APC (23/28, 82.1%, p=0.001), FHIT (24/28, 85.7%, p=.0001), p15 (25/28, 89.2%, p=0.045), p16 (19/28, 67.9%, p=0.037), and E-cadherin (22/28, 78.5%, p=0.0008). The average specificity was 90%, 86%, 96%, 86%, and 100%, respectively. There was no significant association between methylation and hepatitis viral infection for any of the genes tested in this study. Plasma DNA can be reliable for testing methylation profile in liver cancer patients in this population. Future studies on a larger sample size should investigate methylation profile in populations with higher rates of HBV, HCV, and other risk factors.

KW - Egypt

KW - HCC

KW - Liver

KW - Meththylation

KW - Plasma

KW - Tumor tissue

UR - http://www.scopus.com/inward/record.url?scp=74749099086&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=74749099086&partnerID=8YFLogxK

U2 - 10.1016/j.yexmp.2009.09.012

DO - 10.1016/j.yexmp.2009.09.012

M3 - Article

VL - 88

SP - 107

EP - 111

JO - Experimental and Molecular Pathology

JF - Experimental and Molecular Pathology

SN - 0014-4800

IS - 1

ER -